Bayer Initiates Phase I Study Targeting GPC3 with Actinium-225 Radiopharmaceutical in Patients with Advanced Hepatocellular Carcinoma

Bayer announced the initiation of a Phase I clinical trial with 225Ac-GPC3, an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing glypican-3 (GPC3) in patients with advanced HCC.